The 2016 classification also identified other molecular alterations associated with DMGs, such as Tumor Protein 53 (TP53), Alpha-Thalassemia/mental Retardation, and X-linked (ATRX) mutations, which further contributed to the understanding of the molecular landscape of DMGs [24]. The gene discussed is TP53; the disease is Alpha-thalassemia.